Experienced in Hairy Cell Leukemia (HCL)

Dr. John M. Pagel

Hematology Oncology
1221 Madison St, Suite 1020, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Hairy Cell Leukemia (HCL)
1221 Madison St, Suite 1020, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Pagel is a Hematologist Oncology provider in Seattle, Washington. Dr. Pagel is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pagel is currently accepting new patients.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO

Locations

1221 Madison St, Suite 1020, Seattle, WA 98104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

164 Total Publications

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Journal: JCO oncology practice
Published: March 20, 2025
Similar Doctors
Distinguished in Hairy Cell Leukemia (HCL)
Dr. John A. Keech
Hematology Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. John A. Keech
Hematology Oncology
4545 Point Fosdick Dr Nw, Suite 215, 
Gig Harbor, WA 
 (24.5 miles away)
253-530-8060
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Keech is a Hematologist Oncology provider in Gig Harbor, Washington. Dr. Keech is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Lung Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Keech is currently accepting new patients.

David M. Aboulafia
Advanced in Hairy Cell Leukemia (HCL)
Dr. David M. Aboulafia
Hematology Oncology | Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. David M. Aboulafia
Hematology Oncology | Hematology | Oncology

Virginia Mason Medical Center

925 Seneca St, 
Seattle, WA 
 (0.2 miles away)
206-223-6600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Aboulafia is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Aboulafia is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Non-Hodgkin Lymphoma, Anal Cancer, Kaposi Sarcoma, B-Cell Lymphoma, and Splenectomy. Dr. Aboulafia is currently accepting new patients.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Nehal Masood
Hematology Oncology | Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Nehal Masood
Hematology Oncology | Hematology | Oncology

Multicare Health System

317 Mlk Jr Way, Multicare Social Work Serv, 
Tacoma, WA 
 (25.0 miles away)
253-403-1126
Languages Spoken:
English, Castilian, Hindi, Mandarin, Spanish, Swedish, Tamil, Urdu, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Nehal Masood is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Masood is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Angiosarcoma. Dr. Masood is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pagel's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile